Devices and technology: Glycemic control

People with type 1 diabetes treated with multiple daily insulin injections struggle to achieve guideline-recommended targets for time in hypoglycemia while simultaneously reaching their glycated hemoglobin goals, researchers report.

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

What does the proliferation of diabetes self-management and monitoring technologies in pediatric care mean for the future of adult services? Katharine Barnard looks at the situation in England. 

Get more on: Devices and technology | Pediatric diabetes

The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.

DIY closed-loop insulin delivery has provoked controversy within the diabetes community, raising questions around patient empowerment, safety and liability, and whether the regulatory process remains fit for purpose in a technological age. medwireNews takes a look at the issues.

This 15-minute case presents the identification of problematic hypoglycemia and the appropriate use and monitoring of different technologies in the context of reducing the occurrence and risk of hypoglycemia.

Get more on: Hypoglycemia | Devices and technology | Pediatric diabetes

This slide set describes a study of flash glucose monitoring in pregnant women with diabetes, which demonstrates clinical accuracy versus self-monitoring of blood glucose and a high level of acceptability by the patients [access the slides].
Funded by an educational grant from Abbott Diabetes Care.

In this paper, the authors report on the current scientific evidence on the effectiveness of continuous glucose monitoring sensor technology in the prevention of severe hypoglycemia and hypoglycemia unawareness [read more].
Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

Get more on:  Devices and technology | Diabetic complications | Type 1 diabetes

Advisory Board member Katharine Barnard scrutinizes the opinion that clinicians should rely on glycemic outcomes when weighing the decision to prescribe a diabetes device [read more].

Get more on: Devices and technology | Glycemic control in type 1 diabetes | Glycemic control in type 2 diabetes

This article evaluates the potential long-term effect of two different color indication methods for self-monitoring of blood glucose on metabolic parameters in insulin-treated type 2 diabetes [read more].
Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Get more on:  Devices and technology | Type 2 diabetes